OKYO Pharma director granted 5,000 shares

OKYO Pharma Ltd director John P Brancaccio reported a grant of 5000 shares of common stock on 2026-07-21.

Accepted by SEC EDGAR 07/23/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma Ltd director John P Brancaccio reported a grant of 5000 shares of common stock on 2026-07-21. The award, coded as a “grant, award, or other acquisition,” was priced at $1.4770 per share and increased his direct holdings to 35201 shares. The filing’s Rule 10b5-1 checkbox was not marked as being under a trading plan.

Insider Trade Summary

Grant/Award: 5,000 shares

Grant/Award 1 txn

Insider BRANCACCIO JOHN P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	5,000	$1.477	$7K

Holdings After Transaction: COMMON STOCK — 35,201 shares (Direct)

Key Figures

Shares acquired: 5000.0000 shares Grant price per share: $1.4770 Shares owned after transaction: 35201.0000 shares

3 metrics

Shares acquired 5000.0000 shares Grant of common stock on 2026-07-21

Grant price per share $1.4770 Value assigned to the common stock award

Shares owned after transaction 35201.0000 shares Direct holdings following the reported grant

Key Terms

Form 4, Grant, award, or other acquisition, non-derivative, Rule 10b5-1

4 terms

Form 4 regulatory

"The director’s equity award is reported on <b>Form 4</b>."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Grant, award, or other acquisition regulatory

"The transaction code description is <b>Grant, award, or other acquisition</b>."

non-derivative financial

"The common stock is classified as a <b>non-derivative</b> security in the filing."

Rule 10b5-1 regulatory

"A checkbox indicates whether trades are under a <b>Rule 10b5-1</b> plan."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OKYO (OKYO) director John P Brancaccio report?

John P Brancaccio reported a grant of 5000 common shares of OKYO Pharma Ltd on 2026-07-21 at $1.4770 per share. This award increased his direct ownership position to 35201 shares of OKYO common stock.

Was the OKYO (OKYO) Form 4 transaction made under a Rule 10b5-1 plan?

The Form 4 indicates the transaction was not affirmed under a Rule 10b5-1 plan, as the related checkbox is not marked. This means the reported stock grant is not disclosed as part of a pre-arranged trading plan.

How many OKYO (OKYO) shares does John P Brancaccio own after this Form 4?

Following the reported grant, John P Brancaccio directly holds 35201 shares of OKYO Pharma Ltd common stock. This figure reflects his post-transaction ownership as disclosed in the Form 4’s “shares beneficially owned following reported transaction” field.

What type of security is involved in the latest OKYO (OKYO) Form 4 filing?

The transaction involves common stock classified as a non-derivative security. The Form 4 reports a direct acquisition of 5000 shares, rather than options or other derivative instruments, and updates the director’s common stock holdings accordingly.

Is the OKYO (OKYO) Form 4 transaction a market purchase or an equity award?

The transaction is coded “A” as a grant, award, or other acquisition, indicating an equity award rather than an open-market purchase. The director received 5000 shares at a stated value of $1.4770 per share, increasing his direct holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRANCACCIO JOHN P

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	07/21/2026		A		5,000	A	$1.477	35,201	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John Brancaccio	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)